Palvella Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 151.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.18B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin ...